Cipla Ltd

USFDA inspection update

• USFDA completed follow-up cGMP inspection at Pithampur facility from 17 to 25 Aug 2026.
• Seven Form 483 observations were issued; Cipla will address them within the stipulated timeframe.
• Company to work closely with USFDA to address the observations.

Overview

• Amalgamation of a wholly owned subsidiary into the parent.
• Transferor's equity shares cancelled; no new shares issued.
• Appointed Date: 01.04.2026.

Rationale

• Consolidation and pooling of resources for economies of scale and cost savings.
• Greater integration to maximise shareholder value and competitive positioning.
• Improved cash management and access to cash flows.
• Cost rationalization and simplified processes reducing overheads.

Key Terms

• Type: Amalgamation; Appointed Date: 01.04.2026.
• Transferor is wholly owned by Transferee.
• No equity issue or allotment on amalgamation.
• NCLT order dated 18 Aug 2026; directions issued.
• Meetings of shareholders/creditors dispensed with for Transferor.
• No secured creditors in Transferor; one unsecured creditor for Rs 22,683.
• Transferee's unsecured creditors: 2,204.85 crores; rights not affected.
• Post-merger net worth remains positive.

Financial impact

• Assets and liabilities of Transferor transferred to Transferee.
• Creditors of Transferee not affected; claims unchanged.
• Transfer results in streamlined capital structure; no new equity issued.

Stakeholders & Operations

• Shareholders: Transferor's equity cancelled; no issuance to Transferor's shareholders.
• Creditors: Unsecured creditors remain; majority unaffected.
• Operations: Assets and liabilities consolidated; ongoing pharma operations.

Status & Next Steps

• NCLT order pronounced; scheme allowed with directions.
• Regulatory notices to be served; no shareholder meetings required.
• Compliance filings to be completed; effective date to be announced.

ESG ratings update

• SES ESG rating: 69.9 (Adjusted, Grade B) for FY2025-26; 69.3 (Adjusted, Grade B) for FY2024-25.
• NSE rating: 67 (Aspiring) for FY2025-26; 69 (Aspiring) for FY2024-25.
• Decline in NSE rating potentially due to Cipla USA product recall in January 2026.
• Ratings reports received on 10 August 2026 at 1905 IST (SES) and 1527 IST (NSE).

FDA approval for Generic Advair Diskus

• FDA approves Cipla's ANDA for Generic Advair Diskus in 100/50, 250/50, and 500/50 mcg.
• Therapeutically equivalent to Advair Diskus for asthma and COPD.
• Launch expected in Q2 FY2026-27 in the United States.
• Represents Cipla's first DPI approval from its US manufacturing network.
• US DPI market for this product is approximately $908 million (IQVIA).
• Strengthens Cipla's U.S. respiratory capabilities.

Financial Performance

• Q1 revenue was INR 7,119 crores, up 2% year over year.
• EBITDA margin, excluding other income, stood at 16.7% for the quarter.
• Gross margin after material cost was 62.5% for the quarter.
• Profit after tax was INR 789 crores; tax rate 27%.
• R&D spend was INR 486 crores, 6.8% of revenue.
• Net cash was INR 9,494 crores; debt including lease liabilities INR 600 crores.
• Dividend paid this quarter was INR 1,050 crores.
• Marketing and proportional expenditures are now reduced from revenue, effective Apr 1, 2026.

Operating Update and Segments

• One India revenue grew 12% year on year; branded Rx growth 15.4% per IQVIA.
• Chronic mix increased to 60.4% year on year; 33 brands over INR 100 crores.
• US revenue was USD 162 million; Ventolin generic launched.
• Pipeline includes four significant launches: three respiratory assets and one peptide.
• Two filings from US facilities; one from Goa; Ventolin ramping.
• South Africa private market grew 6.5%; tender declines; currency effects hedged.
• EMEU grew 5% year on year in USD terms; margins remained stable.
• Regulatory: US FDA GMP inspection at Verna Goa facility classified as VAI; Invagen NY had one Form 483; Indore reinspection expected.

U.S. and Regulatory

• Ventolin ramp expected toward end of the financial year.
• Four significant launches expected in FY27; three respiratory assets plus a peptide.
• FDA inspections: Verna Goa GMP inspection = VAI; Invagen NY one 483; Indore reinspection planned.

Balance Sheet and Cash Flow

• As of 30 June 2026, debt including lease liabilities was INR 600 crores.
• Net cash and cash equivalents were INR 9,494 crores.
• Dividend paid this quarter was INR 1,050 crores.
• Marketing and proportional expenditures are now presented as a deduction from revenue.

Guidance and Outlook

• FY27 EBITDA margin guidance remains 18.5% to 20%.
• US launches expected to support revenue trajectory toward a $1 billion exit run-rate.
• Lanreotide regulatory timeline remains uncertain and not included in Q4 projections.

Q&A Highlights

• Accounting change increased reported growth by about 4%; India Rx growth around 12%.
• South Africa tender drag; private market growth outpaced market; currency hedging in place.
• Yurpeak INR 80 crores in Q1; growth aided by expanded distribution.
• Lanreotide remediation and site transfer work in parallel; timing uncertain.
• Intent to deploy capital via capex, R&D, in-licensing, and selective M&A.

Risks and Watchpoints

• Tender risk in South Africa persists; potential revenue impact.
• Regulatory approvals and ramp timing for US launches could cause delays.
• War-related cost impact estimated at about 1% to 2% of revenue.
• Competition risk for Ventolin and significant respiratory assets.

Grant details

• Grant of 5,530 ESOS 2013-A stock options at INR 2 price; vesting 2 years from grant.
• ESAR 2021: 19,179 ESARs; 3-year graded vesting; exercise price INR 2; 5-year exercise period from vesting.
• Board meeting held today 9:15–13:00 IST to approve the grants under ESOS 2013-A and ESAR 2021.

SMP status change

• Mr. Sanjay Joseph, Head – API Business, ceases to be Senior Managerial Personnel with effect from 24 July 2026.
• Reason: change in reporting of Mr. Sanjay Joseph.
• Effective date of cessation: 24 July 2026.

CFO transition and appointment

• Ashish Adukia relinquishes CFO and KMP roles; effective close of business 23 July 2026.
• Dinesh Jain appointed Global CFO and KMP, effective 24 July 2026.
• Ashish Adukia transitions to internal leadership role within Cipla.
• Dinesh Jain previously Head – Corporate Finance; over three decades of experience.